Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Taiwan Mitochondrion Applied Technology Co. Ltd. currently has 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These active matters are distributed across 4 distinct examiners and 2 distinct art units. This distribution indicates that while the workload is spread among several individuals, the technical focus is concentrated within a limited number of art units.
The busiest examiner for this portfolio is TINSLEY, BRENDAN THOMAS, who is responsible for 1 pending office action. Because each of the 4 distinct examiners handles exactly the same number of pending actions, the workload is perfectly balanced across the examining staff. This suggests a diverse prosecution strategy where no single examiner holds a majority of the pending cases.
The presence of 2 distinct art units for the active actions implies that multiple examiners are working within the same technical groups. Practitioners should monitor these 2 art units to understand the specific examination trends affecting the company's Biotechnology & Pharmaceuticals applications. The current prosecution footprint involves a balanced distribution of work across the assigned personnel.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TINSLEY, BRENDAN THOMAS | 1 | 58.7% | +73.9% |
| MELLER, MICHAEL V | 1 | 47.1% | +28.2% |
| KIM, TAEYOON | 1 | 51.5% | +52.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17948007 | COMPOSITION COMPRISING MITOCHONDRIA AND USE THEREOF FOR REPAIRING CARTILAGE DAMAGE OR IMPROVING OSTEOARTHRITIS | MELLER, MICHAEL V | — |
| 17912336 | USE OF MITOCHONDRIA TO PROMOTE WOUND REPAIR AND/OR WOUND HEALING | KIM, TAEYOON | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18844740 | COMPOSITION FOR ORAL DAMAGE MITIGATION, USE THEREOF, AND MANUFACTURING METHOD THEREOF | TINSLEY, BRENDAN THOMAS | — |
| 17948007 | COMPOSITION COMPRISING MITOCHONDRIA AND USE THEREOF FOR REPAIRING CARTILAGE DAMAGE OR IMPROVING OSTEOARTHRITIS | MELLER, MICHAEL V | — |
| 17912336 | USE OF MITOCHONDRIA TO PROMOTE WOUND REPAIR AND/OR WOUND HEALING | KIM, TAEYOON | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18844740 | COMPOSITION FOR ORAL DAMAGE MITIGATION, USE THEREOF, AND MANUFACTURING METHOD THEREOF | TINSLEY, BRENDAN THOMAS | — | §112 | Non-Final OA | — | Pending | Sep 06, 2024 |
| 17948007 | COMPOSITION COMPRISING MITOCHONDRIA AND USE THEREOF FOR REPAIRING CARTILAGE DAMAGE OR IMPROVING OSTEOARTHRITIS | MELLER, MICHAEL V | 1655 | §101§103 | Non-Final OA | — | Pending | Sep 19, 2022 |
| 17912336 | USE OF MITOCHONDRIA TO PROMOTE WOUND REPAIR AND/OR WOUND HEALING | KIM, TAEYOON | 1631 | §103§112 | Non-Final OA | — | Pending | Sep 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial